Anthem

Anthem predicts human leukocyte antigen class I (HLA-I) peptide binding to support identification of epitopes for CD8+ T cell responses in neopeptide-based immunotherapy and personalized cancer vaccine development.

Key Features:

• Integration of experimental data: Incorporates mass spectrometry-derived immunopeptidomic data and large-scale datasets to inform binding predictions.
• Customizable machine learning models: Builds and tailors machine learning models to specific datasets and research questions for HLA-I binding prediction.
• Comprehensive evaluation: Evaluates models on independent and experimental datasets and reports performance using area under the curve (AUC) comparable to or exceeding contemporary tools.

Scientific Applications:

• Neopeptide-based immunotherapy: Identifies candidate neopeptides presented by HLA-I for cancer immunotherapy studies.
• Epitope identification for CD8+ T cells: Predicts HLA-I binders that are potential epitopes capable of eliciting CD8+ T cell responses.
• Personalized cancer vaccine development: Supports selection of HLA-I-presented epitopes for individualized vaccine design.

Methodology:

Integrates mass spectrometry-derived immunopeptidomic data with machine learning to construct predictive models of HLA-I peptide binding and evaluates models on independent and experimental datasets using area under the curve (AUC).